Abstract P083

Hodgkin Lymphoma in Older Patients (HoOP)- A European Retrospective Study

Introduction: Older (≥60 year old (yo)) patients with classical Hodgkin Lymphoma (CHL) comprise 20% of all patients with the condition and have poorer outcomes than younger patients. Older patients far best when treated with standard doses of conventional chemotherapy but are less likely to receive this thus accurate identification of patients most likely to tolerate this approach is critically important. There is also a wide variety in treatment regimens used for older CHL patients with a paucity of specific guidance for clinicians.

Methods: HoOP (Hodgkin Lymphoma in Older Patients), a European retrospective data collection project, has been established to characterise pre-treatment comorbidities, treatment-related toxicity and survival following treatment for older CHL patients. Patients diagnosed with CHL at 60 years of age or older between the 1st of January 2010 and 31st of December 2023 will be included and data will be collected pseudo-anonymously at sites by clinicians. The primary objective will be event-free survival of the entire group by age. Other survival objectives will include survival according to treatment initiated and diagnostic era. Toxicity objectives will include description of bleomycin use and bleomycin pulmonary toxicity (BPT), rate of unplanned hospital admissions and infections and non-relapse mortality. We will examine if there is a correlation between baseline patient characteristics and choice of chemotherapy regimen and assess outcomes from brentuximab vedotin and checkpoint inhibitors. Characteristics of the whole population and treatment groups will be described and compared using appropriate statistical tests (chi-squared or Fisher’s exact for discrete variables and t-tests or Kruskal Wallis tests for continuous variables). Statistical power to determine outcomes based on regimen used has been based on the accrual of at least 100 patients per treatment group. Any analyses comparing treatment groups will be adjusted for potential confounding factors including age and comorbidities.

Future Plans: HoOP has been adopted as an official EHA lymphoma SWG project and we are keen to engender international collaboration to maximise data accrual and allow for statistically powerful comparison of patient factors and outcomes. We plan commencement of data entry at 27 participating United Kingdom hospital trusts and 8 hospital sites in the Republic of Ireland by the 1st of July 2024 with data input ongoing until the 1st of October 2025.

Authors

Aisling Barrett, Amy A. Kirkwood, Cathy Burton, Ruth Clifford, Robert Henderson, Pam McKay, Wendy Osborne, Nimish Shah, Graham P. Collins